Global Down Syndrome Market Insights, Epidemiology and Market Forecast Report 2018-2027 - ResearchAndMarkets.com

The "Down Syndrome - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.

Down Syndrome - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Down Syndrome in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Down syndrome from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

The Down Syndrome market report gives the thorough understanding of the Down syndrome by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Down syndrome in the US, Europe, and Japan.

Key Topics Covered:

1. Key Insights

2. Down syndrome: Market Overview at a Glance

3. Down syndrome: Disease Background and Overview

4. Epidemiology and Patient Population

5. Country Wise-Epidemiology of Down syndrome

6. France

7. Current Treatment Practices

8. Unmet needs

9. Emerging Therapies

10. Down syndrome: 7 Major Market Analysis

11. The United States Market Outlook

12. Japan: Market Outlook

13. Market Drivers

14. Market Barriers

15. Appendix

Companies Mentioned

• Eisai
• Transition Therapeutics Ireland Limited
• Balance Therapeutics
• AC Immune

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/68qtvk/global_down?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181029005407/en/